These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16222588)
41. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Keogh A; Strange G; Kotlyar E; Williams T; Kilpatrick D; Macdonald P; Brown K; Pidoux A; Kermeen F; Steele P; Dalton B; Gabbay E Intern Med J; 2011 Mar; 41(3):235-44. PubMed ID: 21118410 [TBL] [Abstract][Full Text] [Related]
42. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
43. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. Alp S; Schlottmann R; Bauer TT; Schmidt WE; Bastian A AIDS; 2003 Jul; 17(11):1714-5. PubMed ID: 12853763 [No Abstract] [Full Text] [Related]
45. Pulmonary arterial hypertension: the race for the most effective treatment. McLaughin VV; Hoeper MM Am J Respir Crit Care Med; 2005 Jun; 171(11):1199-201. PubMed ID: 15914567 [No Abstract] [Full Text] [Related]
46. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127 [TBL] [Abstract][Full Text] [Related]
48. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882 [TBL] [Abstract][Full Text] [Related]
49. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis]. Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870 [TBL] [Abstract][Full Text] [Related]
50. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension]. Montani D; Humbert M Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056 [No Abstract] [Full Text] [Related]
51. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496 [TBL] [Abstract][Full Text] [Related]
52. Management of pulmonary arterial hypertension with a focus on combination therapies. Benza RL; Park MH; Keogh A; Girgis RE J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411 [TBL] [Abstract][Full Text] [Related]
53. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627 [TBL] [Abstract][Full Text] [Related]
54. Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. Ried M; Potzger T; Neu R; Sziklavari Z; Szöke T; Liebold A; Hofmann HS; Hoenicka M Cardiovasc Drugs Ther; 2014 Feb; 28(1):45-51. PubMed ID: 24193244 [TBL] [Abstract][Full Text] [Related]
55. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension. Sağ S; Yeşilbursa D; Güllülü S Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528 [TBL] [Abstract][Full Text] [Related]
56. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527 [TBL] [Abstract][Full Text] [Related]
57. An evidence-based approach to the management of pulmonary arterial hypertension. Coyne TC Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019 [No Abstract] [Full Text] [Related]
58. [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. Shmalts AA; Gorbachevsky SV Ter Arkh; 2020 Dec; 92(12):80-85. PubMed ID: 33720578 [TBL] [Abstract][Full Text] [Related]
59. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251 [TBL] [Abstract][Full Text] [Related]
60. Sildenafil for pulmonary hypertension. Lee AJ; Chiao TB; Tsang MP Ann Pharmacother; 2005 May; 39(5):869-84. PubMed ID: 15827074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]